EUVIMEDEUVIMED entdecken
Crossref

Elexacaftor/tezacaftor/ivacaftor in liver or kidney transplanted people with cystic fibrosis using tacrolimus, a drug-drug interaction study

Renske van der Meer, Erik B Wilms, Margot N Eggermont, Helena M Paalvast, Matthijs van Luin, Richard C J M van Rossen, Harry G M Heijerman

Journal of Cystic Fibrosis · 2024

DOI: 10.1016/j.jcf.2024.01.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2024. Verfasst von Renske van der Meer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology and Adult CF Centre, Haga Hospital, Els Borst-Eilersplein 275, The Hague 2545 AA, The Netherlands. Electronic address: r.va…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Tacrolimus, Drug Interactions, Benzodioxoles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The use of elexacaftor/tezacaftor/ivacaftor (ETI) in people with cystic fibrosis (pwCF) after solid organ transplantation is controversial because of potential drug-drug interactions (DDI) with tacrolimus. We aimed to improve insight into the safety and clinical benefits of co-administration of ETI and tacrolimus in liver or kidney transplanted adult pwCF. METHODS: In 5 pwCF, tacrolimus concentrations were monitored during 2 weeks before and 4 weeks after starting ETI treatment. Trough levels, area under the curve (AUC) and clinical effect of ETI were investigated. During the study (6 weeks in total) adverse events were monitored. RESULTS: The DDI between tacrolimus and ETI resulted in an increased exposure of tacrolimus in all subjects, the dose adjusted AUC0-24h was 1.79 (median) times higher at the end of the study. Five dose adjustments were performed in 4 subjects in order to attain tacrolimus target range. No adverse events were reported and all subjects showed clinical improvement during ETI treatment. CONCLUSION: The clinical value of ETI treatment in kidney and liver transplanted pwCF is clear. The use of ETI may increase tacrolimus levels moderately. Therefore, we recommend close monitoring of tacrolimus trough levels in patients who start ETI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisTacrolimusDrug InteractionsBenzodioxolesQuinolonesLiver TransplantationImmunosuppressive AgentsKidney TransplantationAminophenolsIndolesHumansMaleFemaleAdultPyrazolesDrug CombinationsPyridinesPyrrolesQuinolinesYoung AdultDrug MonitoringPyrrolidines

Stichwörter der Autor:innen

Cystic fibrosisDrug-drug interactionElexacaftor/tezacaftor/ivacaftorSolid organ transplantTacrolimus

Substanzen

TacrolimusBenzodioxolesQuinolonesImmunosuppressive AgentsAminophenolsIndolesPyrazolesDrug CombinationselexacaftorPyridines

Autor:innen und Institutionen

  • Department of Pulmonology and Adult CF Centre, Haga Hospital, Els Borst-Eilersplein 275, The Hague 2545 AA, The Netherlands. Electronic address: r.vandermeer@hagaziekenhuis.nl.
  • Central Hospital Pharmacy (Laboratory AHZ), Charlotte Jacobslaan 70, The Hague 2545 AB, The Netherlands.
  • Department of Pulmonology and Adult CF Centre, Haga Hospital, Els Borst-Eilersplein 275, The Hague 2545 AA, The Netherlands.
  • Department of Clinical Pharmacy, University Medical Centre Utrecht, Heidelberglaan 100, Utrecht 3584 CX, The Netherlands.
  • Department of Pulmonology and Adult CF Centre, University Medical Centre Utrecht, Heidelberglaan 100, Utrecht 3584 CX, The Netherlands.

Zitieren

APA

van der Meer, R., Wilms, E. B., Eggermont, M. N., Paalvast, H. M., van Luin, M., van Rossen, R. C. J. M., & Heijerman, H. G. M. (2024). Elexacaftor/tezacaftor/ivacaftor in liver or kidney transplanted people with cystic fibrosis using tacrolimus, a drug-drug interaction study. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2024.01.008

Vancouver

van der Meer R, Wilms EB, Eggermont MN, Paalvast HM, van Luin M, van Rossen RCJM, et al. Elexacaftor/tezacaftor/ivacaftor in liver or kidney transplanted people with cystic fibrosis using tacrolimus, a drug-drug interaction study. Journal of Cystic Fibrosis. 2024. doi:10.1016/j.jcf.2024.01.008

BibTeX
@article{vanderMeer2024,
  author = {van der Meer, Renske and Wilms, Erik B and Eggermont, Margot N and Paalvast, Helena M and van Luin, Matthijs and van Rossen, Richard C J M and Heijerman, Harry G M},
  title = {Elexacaftor/tezacaftor/ivacaftor in liver or kidney transplanted people with cystic fibrosis using tacrolimus, a drug-drug interaction study},
  journal = {Journal of Cystic Fibrosis},
  year = {2024},
  doi = {10.1016/j.jcf.2024.01.008}
}
Kostenlos starten →